Structure Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates as R&D investment accelerated significantly: GAAP EPS was -$0.49 vs. -$0.38 expected, and the net loss of $106.2M was wider than the $79.6M forecast. Operating loss reached $118.6M, primarily due to an 83% YoY surge in R&D expenses to $100.1M, reflecting heavy investment in the aleniglipron (GSBR-1290) program. Despite the bottom-line miss, the company maintains a robust liquidity position with $1.34B in cash and short-term investments, providing a runway through 2028 to support the newly initiated Phase 3 ACCOMPLISH program.